See ratings and reviews when you sign up for an account.

A Multicentre, Randomized, Open-label, Phase III Study Comparing the Efficacy of Oral Glutamine and Calcium-magnesium With Calcium-magnesium Alone in the Prevention of Oxaliplatin-induced Neurotoxicity in Patients With Colorectal Cancer Treated With Oxaliplatin in Adjuvant or 1st Line Metastatic Settings.

This study is currently Recruiting

August 2011 By Sanofi-Aventis

First Recieved on March 15, 2010

Last Updated on August 2, 2011

Sponsor: Sanofi-Aventis
Information provided by: Sanofi-Aventis
Identifier: NCT01087658


Primary Objective: To assess the benefit of glutamine when added to calcium-magnesium on the occurrence of grade 2, 3 and 4 peripheral sensory neuropathy (PSN) related to oxaliplatin with the National Cancer Institute-Common Terminology Criteria for Adverse Event (NCI-CTCAE) scale taking into account the time from start of oxaliplatin at which the first event occurred. Secondary Objective: To determine cumulative dose of oxaliplatin and time when the first occurrence of grade 2, 3 or 4 PSN. To determine the incidence of dose-reductions, dose-delays and discontinuations of oxaliplatin due to PSN grade 3 or 4. To assess effects of glutamine when added to calcium-magnesium on patients-reported outcomes using the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity 12 items questionnaire (FACT/GOG NTX-12) subscale. To evaluate the incidence of diarrhea. To determine Progression Free Survival (PFS) in metastatic patients.

Study Type: Interventional
Study Design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Ages Eligible for Study:18 Years
Genders Eligible for Study:Both
Accepts Healthy Volunteers:No

Inclusion criteria: 1. Histologically- or cytologically- proven adenocarcinoma of the colon or rectum. 2. Disease either in adjuvant or 1st line metastatic setting. 3. Eastern Cooperation Oncology Group (ECOG) performance status inferior or equal to 2. 4. At least 4 weeks following any major surgical procedure(s) and recovery from any surgical sequelae. 5. Electrocardiogram (ECG) with no acute or recent changes within limit of normal range, and not presenting abnormalities contraindicating the proposed chemotherapy. 6. Adequate liver and kidney function: - Total bilirubin inferior to 1.5 ULN - Serum creatinine inferior to 150 umol/L - Creatinine clearance (ClCr) superior to 45 mL/min - ALT/AST inferior to 3 ULN - Alkaline phosphatase inferior or equal to 2 ULN, unless liver metastases are present and documented at baseline by Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) scans (inferior or equal to 3,5 ULN in that case). 7. Adequate hematological function: - Neutrophils superior or equal to 1.5 x 109/L - Platelet count superior or equal to 100 x 109/L - Hemoglobin superior to 9 g/dL Exclusion criteria: 1. Any condition or past medical history that contra-indicates treatment with oxaliplatin, 5-fluorouracil (5-FU), leucovorin (LV) or capecitabine as reported in the approved labeling information. 2. Previous oxaliplatin-based chemotherapy. 3. Previous or current diagnosis of PSN. 4. Concomitant treatments with drugs/ingredients reported to have a potential activity in preventing PSN: carbamazepine, amitriptyline, gabapentin, phenytoin, glutathione, alpha-lipoic acid, celecoxib, amifostine, venlafaxine, vitamin B1 (thiamine), B6 (pyridoxine). 5. History of known allergy to oxaliplatin or other platinum agents, 5-FU, LV or capecitabine. 6. History of known allergy to glutamine or to calcium-magnesium. 7. Participation in another clinical trial with any investigational drug within 30 days prior to study screening. 8. Uncontrolled intercurrent illness: e.g. high blood pressure, unstable angina, symptomatic congestive heart failure (New York Heart Association Classification III or IV), 9. Serious cardiac arrhythmia, diabetes, or active infection. 10. Concurrent active cancer originating from a primary site other than colon or rectum. 11. Presence of any symptom suggesting brain metastasis. 12. Patients who are pregnant or breast-feeding 13. Patients (males and females) with reproductive potential not implementing accepted and effective method of contraception 14. For patient who will receive Bevacizumab: Bevacizumab is contraindicated in patients with known hypersensitivity to any components of the product to Chinese hamster ovary cell product or other recombinant human or humanized antibodies The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.


  • Investigator: Clinical Sciences & Operations - Study Director - Sanofi-Aventis


  • Investigational Site Number 0001

    Greenfield Park, J4V2H1 Canada

  • Investigational Site Number 124-005

    Laval, H7M3L9 Canada

  • Investigational Site Number 124-007

    London, N6A 4L6 Canada

  • Investigational Site Number 124-014

    Moncton, Canada

  • Investigational Site Number 124-004

    Montreal, H2L 4M1 Canada

  • Investigational Site Number 124-006

    Montreal, H1T 2M4 Canada

  • Investigational Site Number 124010

    Montreal, H2W1S6 Canada

  • Investigational Site Number 124-011

    Montreal, H2X 1P1 Canada

  • Investigational Site Number 124-015

    Oshawa, L1G 2B9 Canada

  • Investigational Site Number 124-012

    Ottawa, K1H8L6 Canada

  • Investigational Site Number 124-003

    Quebec, G1R 2J6 Canada

  • Investigational Site Number 124-017

    Rimouski, G5L5T1 Canada

  • Investigational Site Number 124-002

    Toronto, M5G2M9 Canada

  • Investigational Site Number 124-016

    Winnipeg, R2H2A6 Canada

Conditions related to this trial:

Disclaimer: The list and ratings above are for informational purposes only, and is intended to supplement, not substitute for, the expertise and judgment of your physician, pharmacist or other healthcare professional. The goal of the information is to provide you with a comprehensive view of all available treatments, but should not be construed to indicate that use of any one treatment is safe, appropriate, or effective for you. Decisions about use of a new treatment, or about a change in your current treatment plan, should be in consultation with your doctor or other healthcare professional.